UVavse uyimithi ekhuthazayo ye- ADHD . I-FDA ivunyiwe kwaye ifumaneka ukususela ngoJulayi 2007.
Vyvanse kwi-ADHD
UVavse uyinyanga yokwenza unyango kubantu abadala kunye nabantwana abaneminyaka engama-6 ukuya kwe-12 ubudala abane-ADHD.
- Isithako sazo esiyinhloko ngu lisdexamfetamine dimesylate.
- Ingumuthi weprodrug okanye 'imvelaphi engafanelekiyo' ye dextroamphetamine, enye yezinto eziphambili kwi-Adderall, iAdderall XR kunye neeDatesrine Spansules.
- I-Vyvanse ingathathwa kunye okanye ngaphandle kokutya.
- Ukuba umntwana wakho akakwazi ukugwinya ii-capsules zeVivane, ungazivula kwaye uzifefe kwixabiso elincinci lokutya okanye kwii-ounces ezimbalwa zamanzi (enenzuzo kwezinye iinqwelo ze-ADHD ezikhuthazayo, ezingenayo ukuchithwa kotywala).
- I-Vyvanse ifumaneka kumandla asixhenxe aphezulu: 10mg, 20mg, 30mg, 40mg, 50mg, 60mg, kunye no-70mg.
- Nangona abaninzi abantwana baya kuqala iVivanse kwisilinganiso se-30mg, umthamo ophezulu wokuqala ungabonakala ngakumbi xa umntwana wakho etshintshela kuVivanse kwelinye i-ADHD ekhuthazayo.
- UVivvanse ngokuqhelekileyo uyaphoswa njengeVivvance.
- I-Vyvanse nayo i-FDA ivunyelwe ukuphatha ingxaki yokutya ngokutya kwabantu abadala.
Ngokungafani nezinye izikhuthazo, uVivvanse kufuneka adlule esiswini aze ahluthe phambi kokuba asebenze. Oku kuthetha ukuba akuncinci kakhulu ukuba iVavane izakuxhatshazwa kuba iyakwazi ukunyanzelwa, njl, njengaye amanye amayeza e-ADHD.
Enye inzuzo yeVivusse kukuba iphela iiyure ezingama-12, ngelixa amanye amayeza e-ADHD athatha ixesha elide athabatha ixesha lokugqibela kwiiyure ezili-10 ukuya kwezi-12.
Izixwayiso zikaVivanse kunye nemiphumo emibi
Imiphumo emibi yeVivanse ifana nezinye izikhuthazo ze-ADHD kwaye ngokuqhelekileyo zibandakanya iintlungu zesisu, ukuhlanza, ukulahleka kwesisindo, ukunciphisa intlanzi, iintloko, ukulala, kunye nokugwenxa.
Okuthakazelisayo, iimiphumo zecala-ngokukodwa ukondla ukutya-kubonakala zihlawule ngokukhawuleza emva kwexesha.
Njengeminye imithi evuselelayo, iVivvanse akufanele isetyenziswe ngabantwana ngeemeko ezilandelayo: Izifo zentliziyo okanye ukuqina kemitha; i-moderation ukuya kwixinzelelo oluphezulu lwegazi; hyperthyroidism; i glaucoma; imeko ephezulu yokuxhalaba, ukuxhatshazwa okanye ukuphazamiseka. Kwakhona akufanele isetyenziswe ngabantwana abanembali yokusetyenziswa kakubi kweziyobisi, abathabathayo okanye bathathe kwiintsuku eziyi-14 ezedlulileyo (i-monoamine oxidase inhibitor okanye i-MAOI), okanye ngubani ovalelekileyo, okanye uye waphenduka kwamanye amayeza anamandla.
Ukuba Umntwana Wakho uzame Vyvanse
I-Vyvanse inokuba yinto ekhethekileyo xa imithi yengane yakho yangoku ingahlali ixesha elide ngokwalo lonke usuku, okanye ukuba ukhathazekile ukuba umntwana wakho unokusebenzisa kakubi iyeza lakhe.
Imithombo:
> Ukusebenza kunye nokubekezelelana kwe-lisdexamfetamine > dimesylate > (NRP-104) kubantwana abanenkinga yokunakwa kwengqondo / ukungena kwempilo: isigaba III, i-multicenter, i-randomized, i-double-blind, dose-force, i-parallel-study study. UBederman J - Clin Ther - 01-MAR-2007; 29 (3): 450-63.
I-Vyvanse Inkcazelo epheleleyo, uWayne, uPa: Shire US Inc., i-Revised December 2015.